ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
Revolution Medicines' drug daraxonrasib has shown significant survival benefits in Phase III clinical trials for metastatic pancreatic cancer. The drug, which targets the active 'on' state of RAS proteins, nearly doubled median overall survival compared to standard chemotherapy.
Why it matters
This represents a major breakthrough in treating pancreatic cancer, a disease with historically poor outcomes and limited targeted therapy options.
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
The article reports on clinical trial data and industry reception in a professional, technical manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in